Originally published on GenomeWeb/360Dx - The Cellworks Group has announced the results of clinical studies that showed how physicians could leverage the firm's computational biology modeling technology for genomic profiling of tumors and predicting patient response to chemotherapies.
Cellworks Group, Inc. and CancerPOP, LLC, announced data from multiple studies using computational biology modeling to study acute lymphoblastic leukemia (ALL) during the American Society of Hematology 2017 Annual Meeting, as part of the Tata Precision Oncology Program supported by Tata Trusts. Tata Memorial Hospital, Mumbai (TMH) and Tata Medical Centre, Kolkata (TMC) are clinical partners of this program. The computer model predictions will be validated in retrospective and prospective clinical trials and in the lab by CancerPOP based in Gainesville, Florida along with TMH and TMC.
Cellworks Group, Inc. and CancerPOP, LLC today announced data at the American Society of Hematology 2017 Annual Meeting from multiple studies using computational biology to study acute myeloid leukemia (AML). The studies used highly complex genetic and chromosome mutations to build computer digital models of AML patients. The results found that some AML patients may benefit from drugs that are currently indicated for and typically prescribed for other diseases.